Article

FDA approves triamcinolone acetonide

Allergan Inc. has received FDA approval for triamcinolone acetonide injectable suspension 80 mg/ml (Trivaris), a synthetic glucocorticoid corticosteroid with anti-inflammatory action.

Irvine, CA-Allergan Inc. has received FDA approval for triamcinolone acetonide injectable suspension 80 mg/ml (Trivaris), a synthetic glucocorticoid corticosteroid with anti-inflammatory action.

Delivered via intravitreal injection, the drug is used to treat inflammatory conditions, such as temporal arteritis and uveitis, that are unresponsive to topical corticosteroids and that can lead to vision loss.

"[The corticosteroid] marks the first approval for Allergan resulting from our strategic focus on the development of therapies for back-of-the-eye diseases, and we remain committed to bringing forth innovative new treatments for patients suffering from retinal diseases," said Scott Whitcup, MD, Allergan's executive vice president, research and development.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
© 2025 MJH Life Sciences

All rights reserved.